AlphaGen Therapeutics
PrivateLast Round
Series A
Aug 7, 2025
Company Overview
AlphaGen Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series A round in August 2025.
AlphaGen Therapeutics is a biopharmaceutical company that focuses on the discovery, development, manufacturing, and commercialization of innovative targeted radioligand therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AlphaGen Therapeutics Comparables
Compare AlphaGen Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| C-Ray Therapeutics | 88% | |
| AdvanCell | 85% | |
| ARTBIO | 85% |
For institutional investors. Book with your work email.
AlphaGen Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 7, 2025 | ||||
| Seed | Oct 18, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AlphaGen Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Eight Roads Ventures | Seed |
| Eight Roads Ventures China | Seed |
| F-Prime Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Two next-generation alpha therapies are in preclinical studies.
- Apr 21, 2026
Presenting preclinical studies at AACR 2026.
For institutional investors. Book with your work email.
AlphaGen Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AlphaGen Therapeutics's valuation, stock price, and market status.
Is AlphaGen Therapeutics a public or private company?
AlphaGen Therapeutics is a private company.
What is the current stock price of AlphaGen Therapeutics?
AlphaGen Therapeutics is a private company, so its shares have no public market price. Caplight tracks AlphaGen Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AlphaGen Therapeutics worth (valuation)?
Valuation information for AlphaGen Therapeutics is not publicly available.
Can I buy AlphaGen Therapeutics stock?
AlphaGen Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AlphaGen Therapeutics's last funding round?
AlphaGen Therapeutics's most recent funding round was Series A on August 7, 2025.
Who are the main investors in AlphaGen Therapeutics?
Key investors in AlphaGen Therapeutics include Eight Roads Ventures, Eight Roads Ventures China, F-Prime Capital.
Will AlphaGen Therapeutics IPO soon?
No public IPO plans have been announced for AlphaGen Therapeutics.
How can I track AlphaGen Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in AlphaGen Therapeutics's shares on secondary markets.